Journals / Solunum / 2015 / Cilt: 17 - Sayı: 1

Frequency and Factors of Tremor, Palpitation, and Cramp in Patients with COPD and Asthma

Journal
Solunum
Pages
22–28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Another finding of our study is that tolerance did not develop as much as that reported in literature

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To evaluate the frequency and predictability of side effects, including tremor, cramp, and palpitation, due to treatment in patients with chronic obstructive pulmonary disease and asthma.Methods: We prepared a standard questionnaire for 299 patients concerning their diagnosis, treatment, and side effects of the treatment in February 2007 at Hacettepe University, Faculty of Medicine, Department of Pulmonary Diseases.
📊
Key Findings & Data:We prospectively examined the clinical status of the patients and side effects of the treatment at the 15th, 30th, and 180th days of the treatment.Results: In our study, there were 38 (12.7%) patients with drug-induced tremor.
💡
Conclusion & Impact:Another finding of our study is that tolerance did not develop as much as that reported in literature
🔬Design:Survey & Empirical Study
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

To evaluate the frequency and predictability of side effects, including tremor, cramp, and palpitation, due to treatment in patients with chronic obstructive pulmonary disease and asthma.Methods: We prepared a standard questionnaire for 299 patients concerning their diagnosis, treatment, and side effects of the treatment in February 2007 at Hacettepe University, Faculty of Medicine, Department of Pulmonary Diseases. We prospectively examined the clinical status of the patients and side effects of the treatment at the 15th, 30th, and 180th days of the treatment.Results: In our study, there were 38 (12.7%) patients with drug-induced tremor. Of these, 27 (71.1%) had asthma (p=0.004) and 18 (47.4%) had anamnestic palpitation. Drug-induced tremor risk was 15.3 times higher in patients who used a beta-mimetic compared with those who used any drugs. Cramp risk increased with beta-mimetic use only. In our study, drug-induced tremor was still present at the 180th day of examination in 32 (84.2%) patients.Conclusion: This study demonstrated that side effects, including tremor, palpitation, and cramp, were more common in our patients compared with those in other studies. These side effects were directly related to the primary disease and the use of beta-2-agonists. Another finding of our study is that tolerance did not develop as much as that reported in literature

🔖

Cite This Article

DEMİR, S., DEMİR, A. U., ÖZTUNA, D., KALYONCU, A. F. (2015). Frequency and Factors of Tremor, Palpitation, and Cramp in Patients with COPD and Asthma. Solunum, Cilt: 17 - Sayı: 1, 22–28. https://ajindex.com/articles/314303

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Yorgancioglu A, Cruz AA, Bousquet J, Khaltaev N, Mendis S, Chuchalin A, et al. The Global Alliance against Respiratory Diseases (GARD) Country Report. Prim Care Respir J 2014
  2. [CrossRef] 2. Vincent SD, Toelle BG, Aroni RA, Jenkins CR, Reddel HK. Exasperations’ of asthma: a qualitative study of patient language about worsening asthma. Med J Aust 2006
  3. Richard M, Kaufman J. Asthma and other Allergic Disorders. Noble: Textbook of Primary Care Medicine 2001. 4. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996
  4. [CrossRef] 5. Palmqvist M, Ibsen T, Mellen A, Lötvall J. Comparison of relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999
  5. [CrossRef] 6. Shrewsbury S, Hallett C. Salmeterol 100 microg: an analysis of its tolerability in single-and chronic-dose studies. Ann Allergy Asthma Immunol 2001
  6. [CrossRef] 7. Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007
  7. CD001385. 8. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003
  8. [CrossRef] 9. Beeh KM, Wiewrodt R, Salem AE, Buhl R. Efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases. Pneumologie 2000
  9. [CrossRef] 10. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assesment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 2004
  10. [CrossRef] 11. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013
  11. [CrossRef] 12. Decramer ML, Hanania NA, Lötvall JO, Yawn BP. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013
  12. [CrossRef] 13. Global Strategy for Asthma Management and Prevention 2014
  13. Global Initiative for Asthma: (GİNA) 2014. 14. Mandelberg A, Krupnik Z, Houri S, Smetana S, Gilad E, Matas Z, et al. Salbutamol metered-dose inhaler with spacer for